You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

Litigation Details for Astellas US LLC v. Hospira, Inc. (D. Del. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Astellas US LLC v. Hospira, Inc. (D. Del. 2018)

Docket ⤷  Sign Up Date Filed 2018-10-25
Court District Court, D. Delaware Date Terminated 2022-06-01
Cause 35:271 Patent Infringement Assigned To Colm Felix Connolly
Jury Demand Both Referred To Christopher J. Burke
Parties CURIA MISSOURI INC.; SUN PHARMACEUTICAL INDUSTRIES LTD.,
Patents 6,403,567; 8,106,183; 9,085,601; RE47,301
Attorneys Kevin M. Yurkerwich; William R. Zimmerman
Firms Heyman Enerio Gattuso & Hirzel LLP; Law Office of Michael R. Abram
Link to Docket External link to docket
Small Molecule Drugs cited in Astellas US LLC v. Hospira, Inc.
The small molecule drug covered by the patents cited in this case is ⤷  Sign Up .

Details for Astellas US LLC v. Hospira, Inc. (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 External link to document
2019-08-05 105 Patent/Trademark Report to Commissioner of Patents the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,106,183 ;US RE47301 E1 ;US… 2018 1 June 2022 1:18-cv-01675 835 Patent - Abbreviated New Drug Application(ANDA) Both External link to document
2019-09-16 136 Notice of Service Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,106,183 B2, 8,524, 883 B2, and RE 47, 301E filed… 2018 1 June 2022 1:18-cv-01675 835 Patent - Abbreviated New Drug Application(ANDA) Both External link to document
2019-10-25 158 Claim Construction Chart Appendix N 883 Patent Amendment, # 15 Appendix O Patent 9,085,601, # 16 Appendix P Patent 6,403,567, # 17 Appendix… B 301 Patent, # 3 Appendix C 183 Patent, # 4 Appendix D 883 Patent, # 5 Appendix E 301 Patent Prelim …301 Patent Second Prelim Amendment, # 7 Appendix G 301 Patent Amendment, # 8 Appendix H 183 Patent Application… 883 Patent Application, # 12 Appendix L 883 Patent Prelim Amendment, # 13 Appendix M 883 Patent Amendment…Appendix Q Patent 7,671,192, # 18 Appendix R 601 Patent Application, # 19 Appendix S 601 Patent Prelim Amendment External link to document
2020-05-18 256 Notice of Service Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,106,183 B2, 8,524,883 B2, and RE 47,301 E filed … 2018 1 June 2022 1:18-cv-01675 835 Patent - Abbreviated New Drug Application(ANDA) Both External link to document
2018-10-25 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,106,183 ;9,085,601. (nmg) (… 2018 1 June 2022 1:18-cv-01675 835 Patent - Abbreviated New Drug Application(ANDA) Both External link to document
2020-09-29 480 these topics. (See, e.g., United States Patent No. RE47,301) Defendants should have expected that Dr.… 2018 1 June 2022 1:18-cv-01675 835 Patent - Abbreviated New Drug Application(ANDA) Both External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.